Pathogen assay expansion North American expansion of pathogen testing capabilities evidenced by the July 2025 RT-qPCR Measles Panel launch, presenting an opportunity to cross-sell or bundle RT-qPCR panels or related reagents to regional labs and hospitals already tracking infectious disease surveillance.

NDAs and partnerships Historical collaborations such as the SARS-CoV-2 kit extensions and partnerships suggest potential for OEM or co-development deals with diagnostic companies seeking rapid RT-qPCR or NGS library prep solutions to augment their product lines.

NGS workflow demand Experience in RhinoSeq DNA library preparation and AzureSeq RT-qPCR kits indicates strong alignment with customers building or upgrading NGS workflows, enabling opportunities to offer compatibility controls, validation kits, or turnkey library prep solutions.

Strategic portfolio fit With SeqOnce technologies now under broader G3 Genomics portfolio, there is a pathway to leverage Bandit Bio channels for reagent kits, creating co-branded or cross-promoted product offerings to expand reach and reduce go-to-market friction.

SMB and academic potential Revenue scale and lean team size imply potential value in targeting academic labs, contract research organizations, and small to mid-size diagnostics startups seeking nimble, modular RT-qPCR and NGS solutions with short lead times and adaptable kits.